5 Minute Pearls: Psychiatric Disorders and Psychedelic Therapies: Expanding Treatment Options

“I believe we’re at the cusp of a revolution in psychiatry that will transform the way we look at psychiatric illness, one which will force us to reconsider how we evaluate treatment efficacy and significantly expand treatment options for patients. This metamorphosis will be led by the study and use of psychedelics and MDMA,” says Scott T. Aaronson, MD in the 5-minute explanation of the novel and emerging intersection of psychiatric disorders and psychedelic therapies. - - - - Presented by The Journal of Clinical Psychiatry in partnership with ASCP. Scott T. Aaronson, MD is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt in Baltimore, Maryland. Access clinical resources and learn more at Psychiatrist.com.